NEWS 2 Compliant Respiration Monitor
Lead Participant:
ICENI LABS LIMITED
Abstract
NEWS-2 is the latest version of the National Early Warning Score (NEWS), first produced in 2012 and updated in December 2017, which advocates a system to standardise the assessment and response to acute illness. NEWS-2 has received formal endorsement from NHS England and NHS Improvement to become the early warning system for identifying acutely ill patients -- including those with sepsis -- in hospitals in England.
The NEWS-2 is based on an aggregate scoring system in which a score is allocated to physiological measurements. The six simple physiological parameters form the basis of the scoring system:
1\. respiration rate
2\. oxygen saturation
3\. systolic blood pressure
4\. pulse rate
5\. level of consciousness or new confusion\*
6\. temperature.
Respiration Rate (RR) is one of the most important vital-signs for identifying patients at risk of poor medical outcomes, yet, because it cannot be reliably measured, it is infrequently and poorly utilised. Clinical assessment is unreliable with, for example, 52% of doctors missing abnormal RR through "spot" assessment methods. Existing devices to measure RR are cumbersome, reduce patient mobility and can be unreliable. As such, they are rarely used in un-sedated patients.
SPARTA is a non-contact breathing rate monitor that will give medical staff and carers real-time indication of respiration-rate changes.
The device achieves this by continuous RR monitoring, determination of RR change, whether increasing or decreasing from the norm, with the ability to give warnings of deterioration up to an hour in advance of when intervention is needed The device allows data-driven medical decisions and has the potential to save lives.
SPARTA will enable the community, home and other remote setting monitoring of people with respiratory disease and provide a reliable measure of the progression of the disease and indication of when medical intervention is required.
The early indication of the need for medical intervention has been shown to be a significant factor in improving survival rates from respiratory diseases such as CV-19\.
SPARTA is non-contact. It only needs to be placed near to the patient, typically next to or under the bed, allowing remote monitoring of infectious patients with reduced risk to healthcare workers.
Our vision is that SPARTA can reduce morbidity and mortality during respiratory disease and other disease occurrences requiring bed monitoring. In particular, by ensuring timely admission to hospital and thus reducing the burden on hospital services.
The NEWS-2 is based on an aggregate scoring system in which a score is allocated to physiological measurements. The six simple physiological parameters form the basis of the scoring system:
1\. respiration rate
2\. oxygen saturation
3\. systolic blood pressure
4\. pulse rate
5\. level of consciousness or new confusion\*
6\. temperature.
Respiration Rate (RR) is one of the most important vital-signs for identifying patients at risk of poor medical outcomes, yet, because it cannot be reliably measured, it is infrequently and poorly utilised. Clinical assessment is unreliable with, for example, 52% of doctors missing abnormal RR through "spot" assessment methods. Existing devices to measure RR are cumbersome, reduce patient mobility and can be unreliable. As such, they are rarely used in un-sedated patients.
SPARTA is a non-contact breathing rate monitor that will give medical staff and carers real-time indication of respiration-rate changes.
The device achieves this by continuous RR monitoring, determination of RR change, whether increasing or decreasing from the norm, with the ability to give warnings of deterioration up to an hour in advance of when intervention is needed The device allows data-driven medical decisions and has the potential to save lives.
SPARTA will enable the community, home and other remote setting monitoring of people with respiratory disease and provide a reliable measure of the progression of the disease and indication of when medical intervention is required.
The early indication of the need for medical intervention has been shown to be a significant factor in improving survival rates from respiratory diseases such as CV-19\.
SPARTA is non-contact. It only needs to be placed near to the patient, typically next to or under the bed, allowing remote monitoring of infectious patients with reduced risk to healthcare workers.
Our vision is that SPARTA can reduce morbidity and mortality during respiratory disease and other disease occurrences requiring bed monitoring. In particular, by ensuring timely admission to hospital and thus reducing the burden on hospital services.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| ICENI LABS LIMITED | £100,000 | £ 99,990 |
Participant |
||
| SAFESCAN TECHNOLOGIES LTD | ||
| INNOVATE UK | ||
| MACSIM ASSOCIATES LTD |
People |
ORCID iD |
| Siobhan Brady (Project Manager) |